Effect of Carvedilol on Reducing Transtosomab Cardiac Complications

Phase 3

Recruiting

• Conditions: Trastuzumab related cardiomyopathy.; I50.1; Left ventricular failure

• Registration Number: IRCT20190628044046N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 March 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients who have recently been diagnosed with breast cancer (HER2-overexpressing) (stage I to IIIA) and are candidates for adjuvant treatment with trastuzumab.
The ability to have an informed consent.

Exclusion Criteria

Left Ventricular Ejection Fraction (LVEF) baseline less than 50%, history of heart failure.
Contraindication of treatment with or receiving drugs for beta blocker(BB).
cardiomyopathy or valvular heart disease, myocardial infarction, uncontrolled blood pressure.
history of radiotherapy or chest chemotherapy to the chest.
filtration Glomerular volume 30 mL / min / 1.73 m2, which is calculated using the Modification of Diet in Renal Disease (MDRD)method.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
eft ventricular ejection fraction. Timepoint: The end of the anthracycline chemotherapy and then the end of sessions 4, 8, 12 and one month after the end of Herceptin. Method of measurement: Echocardiography.;Metastasis. Timepoint: At the end of follow up. Method of measurement: ???????????.